 ENGLEWOOD, Colo., Aug. 13, 2021 PRNewswire -- Ampio Pharmaceuticals, Inc. NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced a preprint version of a manuscript, LMWF5A Demonstrates an Anti-Inflammatory Mode of Action and Similar Drug Targets to Dexamethasone in Activated PBMC, has been posted on In Review, a preprint platform hosted on Research Square. 